[1][6] The principal clinical indication of drostanolone propionate in the United States as well as international markets was the treatment of advanced inoperable breast cancer in women.

[1] Hormonal treatment is part of the complex therapy for some kind of tumors, particularly the ones associated with hormone-active tissues like breast or prostate cancer.

That is why drugs that block estrogen receptors or decrease their expression on the cell membrane, antiestrogens, could limit the tumor spread and size.

Drostanolone propionate has been FDA approved[7] as an antiestrogenic drug for the treatment of breast cancer.

Due to this fact, women, who usually do not respond well to any AAS, were having much greater chance to survive cancer.

Drostanolone propionate is or has been used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters.

[1] However, since the given dosage for breast cancer was relatively high (200 mg/twice a week),[8] mild virilization including oily skin, acne, voice deepening, hirsutism, and clitoral enlargement could still occur, and marked virilization could manifest with long-term therapy.

[1] The drug has no estrogenic activity and hence has no propensity for causing gynecomastia (in males) or fluid retention.

It also induces a reduction or inhibition of prolactin or estrogen receptors in the breasts, which is linked to its antitumor effects.

[12][1] In Europe, it was specifically marketed in the United Kingdom, Germany, Belgium, France, Spain, Portugal, Italy, and Bulgaria.